{"prompt": "['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', 'Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production', 'by the adrenals. Androgen sensitive prostatic carcinoma responds to treatment that decreases', 'androgen levels. Androgen deprivation therapies, such as treatment with GnRH agonists or', 'orchiectomy, decrease androgen production in the testes but do not affect androgen production', 'by the adrenals or in the tumor. Abiraterone decreased serum testosterone and other androgens', 'in patients in the placebo-controlled clinical trial. It is not necessary to monitor the effect of', 'Abiraterone on serum testosterone levels. Changes in serum prostate specific antigen (PSA)', 'levels may be observed but have not been shown to correlate with clinical benefit in individual', 'patients.', '3.3.2', 'Physical and Chemical Properties', 'Abiraterone acetate is a white to off-white, non-hygroscopic, crystalline powder. Its molecular', 'formula is C26H33NO2 and it has a molecular weight of 391.55. Abiraterone acetate is', 'a', 'lipophilic compound with an octanol-water partition coefficient of 5.12 (Log P) and is', 'practically insoluble in water. The pKa of the aromatic nitrogen is 5.19.', '3.3.3', 'Pharmaceutical Properties and Formulation', 'Zytiga', 'Each Zytiga tablet contains either 250 mg or 500 mg of abiraterone acetate. Abiraterone acetate', 'is designated chemically as (38)-17-(3-pyridinyl) androsta5, 16-dien-3-yl acetate.', 'Zytiga tablets are available in 500 mg film-coated tablets, 250 mg film-coated tablets and', '250 mg uncoated tablets with the following inactive ingredients:', '500 mg film-coated tablets: colloidal silicon dioxide, croscarmellose sodium, hypromellose,', 'lactose monohydrate, magnesium stearate, silicified microcrystalline cellulose, and sodium', 'lauryl sulfate. The coating, OpadryR II Purple, contains iron oxide black, iron oxide red,', 'polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.', '250 mg film-coated tablets: colloidal silicon dioxide, croscarmellose sodium, lactose', 'monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl', 'sulfate. The coating, Opadry\u00ae II Beige, contains iron oxide red, iron oxide yellow,', 'polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.', '250 mg uncoated tablets: colloidal silicon dioxide, croscarmellose sodium, lactose', 'monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl', 'sulfate', 'Yonsa', 'Yonsa (abiraterone acetate) tablets, 125 mg, are white to off-white, oval-shaped tablets', 'debossed with \"125 FP\" on one side.', '3.3.4', 'Clinical Safety', 'Zytiga', 'In a placebo-controlled, multicenter phase 3 clinical trial of patients with metastatic castration-', 'resistant prostate cancer who were using a gonadotropin-releasing hormone (GnRH) agonist', 'or were previously treated with orchiectomy, abiraterone was administered at a dose of 1,000', 'mg daily in combination with prednisone 5 mg twice daily in the active treatment arm (N =', 'Page 16 of 52']['Short Title: ACADEMIC: ADT + Docetaxel vs ADT + Abiraterone', 'Version Date: 13MAR2019', '791). Placebo plus prednisone 5 mg twice daily was given to control patients (N = 394). The', 'median duration of treatment with Abiraterone was 8 months. The most common adverse drug', 'reactions (5%) reported in clinical studies were joint swelling or discomfort, hypokalemia,', 'edema, muscle discomfort, hot flush, diarrhea, urinary tract infection, cough, hypertension,', 'arrhythmia, urinary frequency, nocturia, dyspepsia, and upper respiratory tract infection. The', 'most common adverse drug reactions that resulted in drug discontinuation were aspartate', 'aminotransferase increased, alanine aminotransferase increased, urosepsis and cardiac failure', '(each in <1% of patients taking abiraterone).', 'Adverse reactions and laboratory abnormalities related to mineralocorticoid effects were', 'reported more commonly in patients treated with abiraterone than in patients treated with', 'placebo: hypokalemia 28% versus 20%, hypertension 9% versus 7% and fluid retention', '(edema) 27% versus 18%, respectively. In patients treated with abiraterone, grades 3 to 4', 'hypokalemia occurred in 5% of patients and grades 3 to 4 hypertension was reported in 1% of', 'patients.', 'Cardiovascular Adverse Reactions:', 'The majority of arrhythmias were grade 1 or 2. Grade 3-4 arrhythmias occurred at similar rates', 'in the two arms. There was one death associated with arrhythmia and one patient with sudden', 'death in the abiraterone arm. No patients had sudden death or arrhythmia associated with death', 'in the placebo arm. Cardiac ischemia or myocardial infarction led to death in 2 patients in the', 'placebo arm and 1 death in the abiraterone arm. Cardiac failure resulting in death occurred in', '1 patient on both arms.', 'Hepatotoxicity:', 'Drug-associated hepatotoxicity with elevated ALT, AST, and total bilirubin has been reported', 'in patients treated with abiraterone. Across all clinical trials, liver function test elevations (ALT', 'or AST increases of > 5X ULN) were reported in 2.3% of patients who received abiraterone,', 'typically during the first 3 months after starting treatment. In the phase 3 trial, patients whose', 'baseline ALT or AST were elevated were more likely to experience liver function test', 'elevations than those beginning with normal values. When elevations of either ALT or AST >', '5X ULN, or elevations in bilirubin > 3X ULN were observed, abiraterone was withheld or', 'discontinued. In two instances marked increases in liver function tests occurred. These two', 'patients with normal baseline hepatic function, experienced ALT or AST elevations 15 to 40X', 'ULN and bilirubin elevations 2 to 6 X ULN. Upon discontinuation of abiraterone, both patients', 'had normalization of their liver function tests and one patient was re-treated with', 'ABIRATERONE without recurrence of the elevations. In clinical trials, the following patients', 'were excluded: patients with active hepatitis, patients with baseline ALT and/or AST > 2.5X', 'ULN in the absence of liver metastases, and patients with ALT and/or AST > 5X ULN in the', 'presence of liver metastases. Abnormal liver function tests developing in patients participating', 'in clinical trials were managed by treatment interruption, dose modification and/or', 'discontinuation [see Dosage and Administration (2.2) and Warnings and Precautions (5.3)].', 'Patients with elevations of ALT or AST > 20X ULN were not re-treated.', 'Page 17 of 52']\n\n###\n\n", "completion": "END"}